Randi Y. Leavitt

Randi Y. Leavitt publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Randi Y. Leavitt sits on this spectrum.

Randi Y. Leavitt D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Randi Y. Leavitt sits on this spectrum.

Best Publications

• Wegener granulomatosis : an analysis of 158 patients

  Gary S. Hoffman;Gail S. Kerr;Randi Y. Leavitt;Claire W. Hallahan

  3695
  Citations

• The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)

  Alfonse T. Masi;Alfonse T. Masi;Gene G. Hunder;Gene G. Hunder;J. T. Lie;J. T. Lie;Beat A. Michel

  2772
  Citations

• The American college of rheumatology 1990 criteria for the classification of polyarteritis nodosa

  Robert W. Lightfoot;Robert W. Lightfoot;Beat A. Michel;Daniel A. Bloch;Daniel A. Bloch;Gene G. Hunder;Gene G. Hunder

  1376
  Citations

• Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

  Francisco M Marty;Per Ljungman;Roy F Chemaly;Johan Maertens

  1187
  Citations

• Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

  Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  838
  Citations

• Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.

  Unknown

  479
  Citations

• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

  Joseph J Eron;Benjamin Young;David A Cooper;Michael Youle

  402
  Citations

• Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy

  Diane V. Havlir;Ian C. Marschner;Martin S. Hirsch;Ann C. Collier

  357
  Citations

• Wegener granulomatosis in children and adolescents: Clinical presentation and outcome

  Menachem Rottem;Anthony S. Fauci;Claire W. Hallahan;Gail S. Kerr

  348
  Citations

• Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

  Frances H. Priddy;Deborah Brown;James Kublin;Kathleen Monahan

  329
  Citations

• Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1: A Randomized, Controlled Equivalence Trial

  Jeffrey L. Lennox;Raphael J. Landovitz;Heather J. Ribaudo;Ighovwerha Ofotokun

  325
  Citations

• Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

  Jürgen K Rockstroh;Edwin DeJesus;Jeffrey L Lennox;Yazdan Yazdanpanah

  276
  Citations

• Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

  Jeffrey L. Lennox;Edwin DeJesus;Daniel S. Berger;Adriano Lazzarin

  270
  Citations

• Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide.

  Gary S. Hoffman;Randi Y. Leavitt;Thomas A. Fleisher;James R. Minor

  266
  Citations

• Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener's granulomatosis

  Frederick P. Ognibene;James H. Shelhamer;Gary S. Hoffman;Gail S. Kerr

  264
  Citations

• The management of subglottic stenosis in patients with Wegener's granulomatosis.

  Robert S. Lebovics;Gary S. Hoffman;Randi Y. Leavitt;Gail S. Kerr

  230
  Citations

• Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

  Joseph J. Eron;Jürgen K. Rockstroh;Jacques Reynes;Jaime Andrade-Villanueva

  228
  Citations

• Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

  Jürgen K. Rockstroh;Jeffrey L. Lennox;Edwin Dejesus;Michael S. Saag

  222
  Citations

• A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.

  Per Ljungman;Michael Schmitt;Francisco M Marty;Johan Maertens

  168
  Citations

• A Randomized, Controlled Trial of Indinavir, Zidovudine, and Lamivudine in Adults with Advanced Human Immunodeficiency Virus Type 1 Infection and Prior Antiretroviral Therapy

  Martin Hirsch;Roy Steigbigel;Scholomo Staszewski;John Mellors

  153
  Citations